<SEC-DOCUMENT>0001640334-25-000146.txt : 20250122
<SEC-HEADER>0001640334-25-000146.hdr.sgml : 20250122
<ACCEPTANCE-DATETIME>20250122160621
ACCESSION NUMBER:		0001640334-25-000146
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		7
FILED AS OF DATE:		20250122
DATE AS OF CHANGE:		20250122

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-284407
		FILM NUMBER:		25545978

	BUSINESS ADDRESS:	
		STREET 1:		100 - 740 MCCURDY ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 2P7
		BUSINESS PHONE:		250-765-6424

	MAIL ADDRESS:	
		STREET 1:		100 - 740 MCCURDY ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 2P7

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>lxrp_s3.htm
<DESCRIPTION>S-3
<TEXT>
<html><head><title>lxrp_s3.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman; MARGIN: 0px 7%"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>As filed with the Securities and Exchange Commission on January 22, 2025 </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Registration Statement No. 333- </strong></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549 </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">FORM S-3</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">REGISTRATION STATEMENT</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><em>UNDER </em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><em>THE SECURITIES ACT OF 1933 </em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;"> <p style="text-align:center;margin:0px"><strong><font style="font-size:18pt">LEXARIA BIOSCIENCE CORP.</font></strong></p></td></tr> <tr style="height:15px"> <td> <p style="text-align:center;margin:0px"><strong>(Exact name of registrant as specified in its charter) </strong></p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:top;"> <p style="text-align:center;margin:0px"><strong>Nevada</strong></p></td> <td style="width:10%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:top;"> <p style="text-align:center;margin:0px"><strong>20-2000871</strong></p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="text-align:center;margin:0px"><strong>(State or other jurisdiction of</strong></p> <p style="text-align:center;margin:0px"><strong>incorporation or organization)</strong></p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:center;margin:0px"><strong>(I.R.S. Employer</strong></p> <p style="text-align:center;margin:0px"><strong>Identification Number)</strong></p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>#100 - 740 McCurdy Road</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Kelowna, BC Canada V1X 2P7</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u id="del_ueb4ee7e1-af96-46c6-ad7a-3789df777599">1-250-765-6424</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Address, including zip code, and telephone number, including area code, of the registrant&#8217;s principal executive offices) </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Richard Christopher</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Chief Executive Officer</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Lexaria Bioscience Corp.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>#100 - 740 McCurdy Road</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Kelowna, British Columbia V1X 2P7</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u id="del_u824346eb-b217-4ec9-9dfb-5c7b57020059">1-250-765-6424</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Name, address, including zip code, and telephone number, including area code, of agent for service) </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><em>Copy to: </em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Gregory Sichenzia, Esq.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Avital Perlman, Esq.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Sichenzia Ross Ference Carmel LLP</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>1185 Avenue of the Americas, 31</strong><strong><sup style="vertical-align:super">st </sup></strong><strong>Floor</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>New York, NY 10036</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u id="del_ud75c8be3-6a99-4168-b001-697f0f10f975">Telephone: (212) 930-9700</u></strong>&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>From time to time after this Registration Statement becomes effective. </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Approximate date of commencement of proposed sale to the public) </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. &#9744; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. &#9746; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. &#9744; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. &#9744; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="width:30%;"> <p style="text-align:justify;margin:0px">Large accelerated filer</p></td> <td style="width:20%;"> <p style="text-align:justify;margin:0px">&#9744;</p></td> <td style="width:30%;"> <p style="text-align:justify;margin:0px">Accelerated filer</p></td> <td style="width:20%;"> <p style="text-align:justify;margin:0px">&#9744;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">Non-accelerated filer</p></td> <td> <p style="text-align:justify;margin:0px">&#9746;</p></td> <td> <p style="text-align:justify;margin:0px">Smaller reporting company</p></td> <td> <p style="text-align:justify;margin:0px">&#9746;</p></td></tr> <tr style="height:15px"> <td></td> <td></td> <td> <p style="text-align:justify;margin:0px">Emerging Growth Company</p></td> <td> <p style="text-align:justify;margin:0px">&#9744;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. &#9744; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine. </strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><font style="color:red">The information in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="color:red">SUBJECT TO COMPLETION, DATED JANUARY 22, 2025 </font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PROSPECTUS </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="lxrp_s3img1.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Lexaria Bioscience Corp.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>$50,000,000 </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Common Stock </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Warrants </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Rights </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Units </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">From time to time, we may offer and sell up to $50,000,000 in aggregate of the securities described in this prospectus separately or together in any combination, in one or more classes or series, in amounts, at prices and on terms that we will determine at the time of the offering. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This prospectus provides a general description of the securities we may offer. We may provide specific terms of securities to be offered in one or more supplements to this prospectus. We may also provide a specific plan of distribution for any securities to be offered in a prospectus supplement. Prospectus supplements may also add, update or change information in this prospectus. You should carefully read this prospectus and the applicable prospectus supplement, together with any documents incorporated by reference herein, before you invest in our securities. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our common stock and public warrants are listed on the Nasdaq Capital Market under the symbols &#8220;LEXX&#8221; and &#8220;LEXXW&#8221;, respectively. The last reported sale prices of our common stock and public warrants on the Nasdaq Capital Market on January 21, 2025 were $1.94 per share and $0.60&nbsp;per public warrant, respectively. The aggregate market value of our outstanding common stock held by non-affiliates is approximately $32,538,565&nbsp;based on&nbsp;17,552,594&nbsp;shares of outstanding common stock, of which&nbsp;780,138&nbsp;shares are held by affiliates, and a per share price of $1.94 which was the closing sale price of our common stock as quoted on the Nasdaq Capital Market on January 21, 2025. During the 12 calendar month period that ends on, and includes, the date of this prospectus, we have sold $3,617,059 of our securities pursuant to General Instruction I.B.6 of Form S-3. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Investing in any of our securities involves a high degree of risk. Please read carefully the section entitled &#8220;<u id="del_uab1c92b1-282e-48ff-8d33-672b237599b2">Risk Factors</u>&#8221; on page 8</strong> <strong>of this prospectus, the &#8220;Risk Factors&#8221; section contained in the applicable prospectus supplement and the information included and incorporated by reference in this prospectus. </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>The date of this prospectus is , 2025.</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a name="Toc1"><strong>TABLE OF CONTENTS </strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u id="del_ub8ec52b5-70fc-4602-a709-977c40687350"></u></strong>&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="text-align:center;margin:0px"><strong>Page</strong></p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:bottom;"> <p style="margin:0px"><a href="#ABOUTTHISPROSPECTUS">About This Prospectus</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:right;margin:0px">4</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:bottom;"> <p style="margin:0px"><a href="#WHEREYOUCAN">Where You Can Find More Information</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:right;margin:0px">5</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:bottom;"> <p style="margin:0px"><a href="#INFORMATIONWEINCORPORATE">Information We Incorporate By Reference</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:right;margin:0px">5</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:bottom;"> <p style="margin:0px"><a href="#SPECIALNOTE">Special Note Regarding Forward-Looking Statements</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:right;margin:0px">6</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:bottom;"> <p style="margin:0px"><a href="#LexariaBioscienceCorp">Lexaria Bioscience Corp.</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:right;margin:0px">7</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:bottom;"> <p style="margin:0px"><a href="#RISKFACTORS">Risk Factors</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:right;margin:0px">8</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:bottom;"> <p style="margin:0px"><a href="#USEOFPROCEEDS">Use Of Proceeds</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:right;margin:0px">8</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:bottom;"> <p style="margin:0px"><a href="#DESCRIPTIONOFCAPITALSTOCK">Description Of Capital Stock</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:right;margin:0px">8</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:bottom;"> <p style="margin:0px"><a href="#DESCRIPTIONOFWARRANTS">Description Of Warrants</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:right;margin:0px">10</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:bottom;"> <p style="margin:0px"><a href="#DESCRIPTIONOFRIGHTS">Description Of Rights</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:right;margin:0px">13</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:bottom;"> <p style="margin:0px"><a href="#DESCRIPTIONOFUNITS">Description Of Units</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:right;margin:0px">13</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:bottom;"> <p style="margin:0px"><a href="#PLANOFDISTRIBUTION">Plan Of Distribution</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:right;margin:0px">14</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:bottom;"> <p style="margin:0px"><a href="#LEGALMATTERS">Legal Matters</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:right;margin:0px">16</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:bottom;"> <p style="margin:0px"><a href="#EXPERTS">Experts</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:right;margin:0px">16</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#Toc1">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="ABOUTTHISPROSPECTUS">ABOUT THIS PROSPECTUS </a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or the SEC, using a &#8220;shelf&#8221; registration or continuous offering process. Under this shelf registration process, we may, from time to time, sell any combination of the securities described in this prospectus in one or more offerings up to a total aggregate offering price of $50,000,000. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This prospectus provides a general description of the securities we may offer. We may provide specific terms of securities to be offered in one or more supplements to this prospectus. We may also provide a specific plan of distribution for any securities to be offered in a prospectus supplement. Prospectus supplements may also add, update or change information in this prospectus. If the information varies between this prospectus and the accompanying prospectus supplement, you should rely on the information in the accompanying prospectus supplement. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Before purchasing any securities, you should carefully read both this prospectus and any prospectus supplement, together with the additional information described under the heading &#8220;Information We Incorporate by Reference.&#8221; You should rely only on the information contained or incorporated by reference in this prospectus, any prospectus supplement and any free writing prospectus prepared by or on behalf of us or to which we have referred you. Neither we nor any underwriters have authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. You should assume that the information contained in this prospectus, any prospectus supplement or any free writing prospectus is accurate only as of the date on its respective cover, and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, unless we indicate otherwise. Our business, financial condition, results of operations and prospects may have changed since those dates. This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading &#8220;Where You Can Find More Information.&#8221; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This prospectus and any applicable prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate. We are not making offers to sell common stock or any other securities described in this prospectus in any jurisdiction in which an offer or solicitation is not authorized or in which we are not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unless otherwise expressly indicated or the context otherwise requires, we use the terms &#8220;Lexaria,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or similar references to refer to Lexaria Bioscience Corp. and its subsidiaries. </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#Toc1">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="WHEREYOUCAN">WHERE YOU CAN FIND MORE INFORMATION </a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have filed our registration statement on Form S-3 with the SEC under the Securities Act of 1933, as amended, or the Securities Act. We also file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy any document that we file with the SEC, including the registration statement and the exhibits to the registration statement, at the SEC&#8217;s Public Reference Room located at 100 F Street, N.E., Washington D.C. 20549. You may obtain further information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. Our SEC filings are also available to the public at the SEC&#8217;s web site at www.sec.gov. These documents may also be accessed on our web site at www.lexariabioscience.com. Information contained on our web site is not incorporated by reference into this prospectus and you should not consider information contained on our web site to be part of this prospectus. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This prospectus and any prospectus supplement are part of a registration statement filed with the SEC and do not contain all of the information in the registration statement. The full registration statement may be obtained from the SEC or us as indicated above. Other documents establishing the terms of the offered securities are filed as exhibits to the registration statement or will be filed through an amendment to our registration statement on Form S-3 or under cover of a Current Report on Form 8-K and incorporated into this prospectus by reference. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a name="INFORMATIONWEINCORPORATE"><strong>INFORMATION WE INCORPORATE BY REFERENCE </strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The SEC allows us to &#8220;incorporate by reference&#8221; into this prospectus the information we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Any statement contained herein or in a document incorporated or deemed to be incorporated by reference into this document will be deemed to be modified or superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the statement. We incorporate by reference in this prospectus the following information (other than, in each case, documents or information deemed to have been furnished and not filed in accordance with SEC rules): </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">our Annual Report on <u id="del_u6ced0445-d5ec-4a90-ad22-fc752b6d02bf">Form 10-K</u> for the year ended August 31, 2024, filed on November 26, 2024;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">our Quarterly Report on Form 10-Q for the quarter ended November 30, 2024, filed on January 10, 2025;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">our Current Reports on Form 8-K, filed on <u id="del_u44e06710-8e64-40e2-bc42-bbff9fb1168e">September 5, 2024</u>, <u id="del_u4188db20-739f-4397-b8fb-51a89f9a18a1">October 2, 2024</u>, <u id="del_uc0da288c-7ba3-4d84-8f13-b2e546d8f806">October 16, 2024</u>, <u id="del_u773d3910-2199-4ad0-8034-8300692de6e7">October 18, 2024, December 18, 2024, January 3, 2025 and January 15, 2025</u> (other than any portions thereof deemed furnished and not filed); and</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">our <u id="del_u5fa1a819-9b09-4900-8e2b-2c4f5a392482">Form 8-A12B</u>, filed on January 11, 2021, including any amendments or reports filed for the purpose of updating such description.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We also incorporate by reference each of the documents that we file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, (i) after the date of this prospectus and prior to effectiveness of this registration statement on Form S-3 and (ii) on or after the date of this prospectus and prior to the termination of the offerings under this prospectus and any prospectus supplement. These documents include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements. We will not, however, incorporate by reference in this prospectus any documents or portions thereof that are not deemed &#8220;filed&#8221; with the SEC, including any information furnished pursuant to Item 2.02 or Item 7.01 of our Current Reports on Form 8-K after the date of this prospectus unless, and except to the extent, specified in such Current Reports. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We will provide to each person, including any beneficial owner, to whom a prospectus (or a notice of registration in lieu thereof) is delivered a copy of any of these filings (other than an exhibit to these filings, unless the exhibit is specifically incorporated by reference as an exhibit to this prospectus) at no cost, upon a request to us by writing or telephoning us at the following address and telephone number: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Lexaria Bioscience Corp.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Attn: Corporate Secretary</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#100-740 McCurdy Road, </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Kelowna, British Columbia, Canada V1X 2P7 </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1-250-765-6424</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#Toc1">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="SPECIALNOTE">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Certain matters discussed in this prospectus may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended, or the Securities Act, and the Securities Exchange Act of 1934, as amended, or the Exchange Act, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;may,&#8221; &#8220;expect,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;project,&#8221; &#8220;intend&#8221; and similar expressions are generally intended to identify forward-looking statements. These forward- looking statements include, among other things, statements about: the status, progress and results of our research programs; our ability to obtain regulatory approvals for, and the level of market opportunity for, our product candidates; our business plans, strategies and objectives, including plans to pursue collaboration, licensing or other similar arrangements or transactions; our expectations regarding our liquidity and performance, including our expense levels, sources of capital and ability to maintain our operations as a going concern; the competitive landscape of our industry; and general market, economic and political conditions.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These forward-looking statements are only predictions and we may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, so you should not place undue reliance on our forward- looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation, those discussed under the caption &#8220;Risk Factors&#8221; contained in this prospectus, any prospectus supplement, any applicable free writing prospectus, or under similar heading in the other documents that are incorporated by reference into this prospectus. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results. We have included important factors in the cautionary statements included in this prospectus that could cause actual future results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by these cautionary statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The forward-looking statements contained in this prospectus reflect our views and assumptions only as of the date of this prospectus. Except as required by law, we assume no responsibility for updating any forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#Toc1">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="LexariaBioscienceCorp">Lexaria Bioscience Corp.</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Lexaria Bioscience Corp. is a biotechnology company dedicated to the enhancement of the bioavailability of a broad range of active pharmaceutical ingredients (&#8220;APIs&#8221;) using our patented DehydraTECH<sup style="vertical-align:super">TM</sup>&nbsp;drug delivery-enabling platform technology. DehydraTECH combines APIs with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">DehydraTECH can be used with a wide range of active molecules including glucagon-like peptide-1 drugs (&#8220;GLP-1&#8221;) and glucose-dependent insulinotropic polypeptide drugs (&#8220;GIP&#8221;), vitamins, pain medications, hormones, phosphodiesterase type 5 (&#8220;PDE5&#8221;) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. Our technology can be applied to a variety of therapeutic indications, including diabetes, weight loss, hypertension and heart disease. DehydraTECH can be implemented in a multitude of ingestible or topically administered product formats including oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches. It is suitable for use with a variety of product formats including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">DehydraTECH is a technology incorporated into the formulation and manufacturing process of new or existing orally ingestible and topical products. The procedure involves combining the active ingredient as a delivery &#8220;payload&#8221; together with certain long chain fatty acid-rich triglyceride oils and infusing the mixture into a carrier substrate material. Using controlled dehydration processing, the payload and long chain fatty acid-rich triglyceride oils are reversibly associated together at a molecular level. The newly combined molecules are then integrated into production of the end-product using any number of dosage formats. While the Company&#8217;s primary focus is on pharmaceutical drug products, this technology extends across many product categories including foods, beverages, cosmetics and nutraceuticals. DehydraTECH formulations have been found in some cases to reduce the need for unwanted sweeteners or chemical masking agents used for flavor- and odor-blocking for palatability enhancement purposes, allowing manufacturers to create low-sugar products with fewer calories and artificial sweeteners.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has developed extensive experience from the formulation and production of its demonstration products, in various formats, that enables it to provide expert advice to our licensees on the integration of DehydraTECH in their products for the purpose of providing more palatable and efficient delivery of bioactive molecules.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Lexaria supports our licensee&#8217;s products with our technology. A part of our business plan is to encourage new and existing industry participants to license and utilize DehydraTECH to enable enhanced performance of their developmental and commercial stage products. These products cross a wide range of bioactive molecules including GLP-1/GIPs, NSAID&#8217;s, nicotine and cannabidiol (&#8220;CBD&#8221;) with additional molecules of interest continually being evaluated.&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Corporate Information</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our principal executive offices are located at 100 &#8211; 740 McCurdy Road, Kelowna, British Columbia, Canada, V1X 2P7. Our telephone number is 1-250-765-6424. We maintain a website at&nbsp;<u id="del_u14f50de3-e7eb-46e2-908c-7d891b6cde1b">www.lexariabioscience.com</u>. The information contained on our website is not, and should not be interpreted to be, a part of this prospectus. Lexaria Bioscience Corp. is a British Columbia based reporting issuer in Canada and as such, we are required to file certain information and documents at&nbsp;<u id="del_ud4c7c8be-4c90-4d2e-8680-4a9b5f613331">www.sedarplus.ca</u>.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#Toc1">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="RISKFACTORS">RISK FACTORS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">An investment in our common stock involves a high degree of risk. You should carefully consider the risks set forth under the section captioned &#8220;Risk Factors&#8221; contained in our Annual Report on Form 10-K for the year ended August 31, 2024, which is incorporated by reference into this prospectus, and in the other reports that we file with the SEC and incorporate by reference into this prospectus, before deciding to invest in our common stock. The risks and uncertainties we have described are not the only ones we face.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If any of the events described in these risk factors actually occurs, or if additional risks and uncertainties that are not presently known to us or that we currently deem immaterial later materialize, then our business, prospects, results of operations and financial condition could be materially adversely affected. In that event, the trading price of our securities could decline, and you may lose all or part of your investment in our securities. The risks discussed include forward-looking statements, and our actual results may differ substantially from those discussed in these forward-looking statements. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="USEOFPROCEEDS">USE OF PROCEEDS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. Unless otherwise specified in any prospectus supplement, we currently intend to use the net proceeds from the sale of our securities offered under this prospectus for working capital and general corporate purposes including, but not limited to, research and development studies and the patent and legal costs associated thereto, potential repurchase of certain of our issued shares and for general working capital purposes. Pending any specific application, we may initially invest funds in short-term marketable securities or apply them to the reduction of indebtedness. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a name="DESCRIPTIONOFCAPITALSTOCK"><strong>DESCRIPTION OF CAPITAL STOCK</strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following information describes the common stock, par value $0.001 per share, of the Company, as well as certain provisions of our articles of incorporation, as amended (the &#8220;Articles of Incorporation&#8221;) and our amended and restated bylaws (&#8220;Bylaws&#8221;). This description is only a summary. You should also refer to our Articles of Incorporation and Bylaws, which have been filed with the SEC as exhibits to the registration statement of which this prospectus forms a part. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Authorized and Outstanding Capital Stock </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our authorized capital stock consists of 220,000,000 shares of common stock, par value $0.001 per share. As of January 21, 2025, there were&nbsp;17,552,594&nbsp;shares of our common stock outstanding.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Common Stock </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are authorized to issue up to a total of 220,000,000 shares of common stock, par value $0.001 per share. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of our stockholders. Holders of our common stock have no cumulative voting rights. Further, holders of our common stock have no pre-emptive or conversion rights or other subscription rights. Upon our liquidation, dissolution or winding-up, holders of our common stock are entitled to share in all assets remaining after payment of all liabilities. As well, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our Board out of our assets which are legally available. Such dividends, if any, are payable in cash, in property or in shares of capital stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The holders of shares of our common stock equal to 33.33% of all of our outstanding capital stock, present in person or by proxy, are necessary to constitute a quorum at any shareholder meeting. If a quorum is present, an action by stockholders entitled to vote on a matter is approved if the number of votes cast in favor of the action exceeds the number of votes cast in opposition to the action. The vote of a majority of our stock held by shareholders present in person or represented by proxy and entitled to vote at the meeting will be sufficient to elect directors or to approve a proposal. The additional shares of our authorized capital stock available for issuance may be issued at times and under circumstances so as to have a dilutive effect on earnings per share and on the equity ownership of the holders of our common stock. The ability of our board of directors to issue additional shares of stock could enhance the board&#8217;s ability to negotiate on behalf of the stockholders in a takeover situation but could also be used by the board to make a change of control more difficult, thereby denying stockholders the potential to sell their shares at a premium and entrenching current management. The following description is a summary of the material provisions of our capital stock. You should refer to our Articles of Incorporation and our Bylaws, each as amended to date, both of which are on file with the SEC as exhibits to previous SEC filings, for additional information. The summary below is qualified by provisions of applicable law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#Toc1">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our common stock is traded on the Nasdaq Capital Market under the symbol &#8220;LEXX&#8221;. The transfer agent and registrar for our common stock is Computershare Trust Company of Canada.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Anti-Takeover Provisions of Nevada State Law</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Certain anti-takeover provisions of Nevada law could have the effect of delaying or preventing a third-party from acquiring us, even if the acquisition arguably could benefit our stockholders.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Nevada&#8217;s &#8220;combinations with interested stockholders&#8221; statutes, NRS 78.411 through 78.444, inclusive, prohibit specified types of business &#8220;combinations&#8221; between certain Nevada corporations and any person deemed to be an &#8220;interested stockholder&#8221; for two years after such person first becomes an &#8220;interested stockholder&#8221; unless the corporation&#8217;s board of directors approves the combination, or the transaction by which such person becomes an &#8220;interested stockholder&#8221;, in advance, or unless the combination is approved by the board of directors and sixty percent of the corporation&#8217;s voting power not beneficially owned by the interested stockholder, its affiliates and associates. Further, in the absence of prior approval certain restrictions may apply even after such two year period. However, these statutes do not apply to any combination of a corporation and an interested stockholder after the expiration of four years after the person first became an interested stockholder. For purposes of these statutes, an &#8220;interested stockholder&#8221; is any person who is (1) the beneficial owner, directly or indirectly, of ten percent or more of the voting power of the outstanding voting shares of the corporation, or (2) an affiliate or associate of the corporation and at any time within the two previous years was the beneficial owner, directly or indirectly, of ten percent or more of the voting power of the then outstanding shares of the corporation. The definition of the term &#8220;combination&#8221; is sufficiently broad to cover most significant transactions between a corporation and an &#8220;interested stockholder.&#8221; These statutes generally apply to Nevada corporations with 200 or more stockholders of record. However, a Nevada corporation may elect in its articles of incorporation not to be governed by these particular laws, but if such election is not made in the corporation&#8217;s original articles of incorporation, the amendment (1) must be approved by the affirmative vote of the holders of stock representing a majority of the outstanding voting power of the corporation not beneficially owned by interested stockholders or their affiliates and associates, and (2) is not effective until 18 months after the vote approving the amendment and does not apply to any combination with a person who first became an interested stockholder on or before the effective date of the amendment. We have made such an election in our original articles of incorporation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Nevada&#8217;s &#8220;acquisition of controlling interest&#8221; statutes, NRS 78.378 through 78.379, inclusive, contain provisions governing the acquisition of a controlling interest in certain Nevada corporations. These &#8220;control share&#8221; laws provide generally that any person that acquires a &#8220;controlling interest&#8221; in certain Nevada corporations may be denied voting rights, unless a majority of the disinterested stockholders of the corporation elects to restore such voting rights. Absent such provision in our bylaws, these laws would apply to us as of a particular date if we were to have 200 or more stockholders of record (at least 100 of whom have addresses in Nevada appearing on our stock ledger at all times during the 90 days immediately preceding that date) and do business in the State of Nevada directly or through an affiliated corporation, unless our articles of incorporation or bylaws in effect on the tenth day after the acquisition of a controlling interest provide otherwise. These laws provide that a person acquires a &#8220;controlling interest&#8221; whenever a person acquires shares of a subject corporation that, but for the application of these provisions of the NRS, would enable that person to exercise (1) one fifth or more, but less than one third, (2) one third or more, but less than a majority or (3) a majority or more, of all of the voting power of the corporation in the election of directors. Once an acquirer crosses one of these thresholds, shares which it acquired in the transaction taking it over the threshold and within the 90 days immediately preceding the date when the acquiring person acquired or offered to acquire a controlling interest become &#8220;control shares&#8221; to which the voting restrictions described above apply.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Nevada law also provides that directors may resist a change or potential change in control if the directors determine that the change is opposed to, or not in the best interests of, the corporation. The existence of the foregoing provisions and other potential anti-takeover measures could limit the price that investors might be willing to pay in the future for shares of our common stock. They could also deter potential acquirers of our Company, thereby reducing the likelihood that you could receive a premium for your common stock in an acquisition.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#Toc1">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Anti-Takeover Effects of Our Articles of Incorporation and Bylaws</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following provisions of our Articles of Incorporation and Bylaws could have the effect of delaying or discouraging another party from acquiring control of us and could encourage persons seeking to acquire control of us to first negotiate with our Board:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">the right of our Board to elect a director to fill a vacancy created by the expansion of the Board or the resignation, death or removal of a director, with our stockholders only allowed to fill such a vacancy if not filled by the Board;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">the ability of our Board to alter our Bylaws without obtaining shareholder approval; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">the requirement that a special meeting of stockholders may be called only by either the President or the Secretary by resolution of the Board of Directors or at the request of stockholders owning a majority of the issued and outstanding capital stock of the Company entitled to vote, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="DESCRIPTIONOFWARRANTS">DESCRIPTION OF WARRANTS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>General </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following description, together with the additional information we include in any applicable prospectus supplement, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which consist of warrants to purchase shares of common stock. Warrants may be offered independently or together with shares of common stock by any prospectus supplement and may be attached to or separate from those securities. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">While the terms we have summarized below will generally apply to any future warrants we may offer under this prospectus, we will describe the particular terms of any warrants that we may offer in more detail in the applicable prospectus supplement. The specific terms of any warrants may differ from the description provided below as a result of negotiations with third parties in connection with the issuance of those warrants, as well as for other reasons. Because the terms of any warrants we offer under a prospectus supplement may differ from the terms we describe below, you should rely solely on information in the applicable prospectus supplement if that summary is different from the summary in this prospectus. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We will issue the warrants under a warrant agreement, which we will enter into with a warrant agent to be selected by us. We use the term &#8220;warrant agreement&#8221; to refer to any of these warrant agreements. We use the term &#8220;warrant agent&#8221; to refer to the warrant agent under any of these warrant agreements. The warrant agent will act solely as an agent of ours in connection with the warrants and will not act as an agent for the holders or beneficial owners of the warrants. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We will incorporate by reference into the registration statement of which this prospectus is a part the form of warrant agreement, including a form of warrant certificate, that describes the terms of the series of warrants we are offering before the issuance of the related series of warrants. The following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement applicable to a particular series of warrants. We urge you to read any applicable prospectus supplement related to the warrants that we sell under this prospectus, as well as the complete warrant agreement that contain the terms of the warrants and defines your rights as a warrant holder. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#Toc1">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We will describe in the applicable prospectus supplement the terms relating to a series of warrants. If warrants for the purchase of shares of common stock are offered, the prospectus supplement will describe the following terms, to the extent applicable: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">the offering price and the aggregate number of warrants offered;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">the total number of shares that can be purchased if a holder of the warrants exercises them;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">the number of warrants being offered with each share of common stock;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">the date on and after which the holder of the warrants can transfer them separately from the related shares of common stock;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">the number of shares of common stock that can be purchased if a holder exercises the warrant and the price at which those shares may be purchased upon exercise, including, if applicable, any provisions for changes to or adjustments in the exercise price and in the securities or other property receivable upon exercise;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">the terms of any rights to redeem or call, or accelerate the expiration of, the warrants;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">the date on which the right to exercise the warrants begins and the date on which that right expires;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">federal income tax consequences of holding or exercising the warrants; and</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">any other specific terms, preferences, rights or limitations of, or restrictions on, the warrants.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Warrants for the purchase of shares of common stock will be in registered form only. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A holder of warrant certificates may exchange them for new certificates of different denominations, present them for registration of transfer and exercise them at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement. Until any warrants to purchase shares of common stock are exercised, holders of the warrants will not have any rights of holders of the underlying shares of common stock, including any rights to receive dividends or to exercise any voting rights, except to the extent set forth under &#8220;Warrant Adjustments&#8221; below. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Exercise of Warrants </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Each holder of a warrant is entitled to purchase the number of shares of common stock, as the case may be, at the exercise price described in the applicable prospectus supplement. After the close of business on the day when the right to exercise terminates (or a later date if we extend the time for exercise), unexercised warrants will become void. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A holder of warrants may exercise them by following the general procedure outlined below: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">deliver to the warrant agent the payment required by the applicable prospectus supplement to purchase the underlying security;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">properly complete and sign the reverse side of the warrant certificate representing the warrants; and</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">deliver the warrant certificate representing the warrants to the warrant agent within five business days of the warrant agent receiving payment of the exercise price.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If you comply with the procedures described above, your warrants will be considered to have been exercised when the warrant agent receives payment of the exercise price, subject to the transfer books for the securities issuable upon exercise of the warrant not being closed on such date. After you have completed those procedures and subject to the foregoing, we will, as soon as practicable, issue and deliver to you the shares of common stock that you purchased upon exercise. If you exercise fewer than all of the warrants represented by a warrant certificate, a new warrant certificate will be issued to you for the unexercised amount of warrants. Holders of warrants will be required to pay any tax or governmental charge that may be imposed in connection with transferring the underlying securities in connection with the exercise of the warrants. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#Toc1">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Amendments and Supplements to the Warrant Agreements </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We may amend or supplement a warrant agreement without the consent of the holders of the applicable warrants to cure ambiguities in the warrant agreement, to cure or correct a defective provision in the warrant agreement, or to provide for other matters under the warrant agreement that we and the warrant agent deem necessary or desirable, so long as, in each case, such amendments or supplements do not materially adversely affect the interests of the holders of the warrants. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Warrant Adjustments </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unless the applicable prospectus supplement states otherwise, the exercise price of, and the number of securities covered by, a warrant for shares of common stock will be adjusted proportionately if we subdivide or combine our common stock, as applicable. In addition, unless the prospectus supplement states otherwise, if we, without payment: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">pay any cash to all or substantially all holders of our common stock, other than a cash dividend paid out of our current or retained earnings;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">issue any evidence of our indebtedness or rights to subscribe for or purchase our indebtedness to all or substantially all holders of our common stock; or</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">issue common stock or additional shares or other securities or property to all or substantially all holders of our common stock by way of spinoff, split-up, reclassification, combination of shares or similar corporate rearrangement;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">then the holders of common stock warrants will be entitled to receive upon exercise of the warrants, in addition to the securities otherwise receivable upon exercise of the warrants and without paying any additional consideration, the amount of shares and other securities and property such holders would have been entitled to receive had they held the common stock issuable under the warrants on the dates on which holders of those securities received or became entitled to receive such additional shares and other securities and property. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Except as stated above, the exercise price and number of securities covered by a warrant for shares of common stock, and the amounts of other securities or property to be received, if any, upon exercise of those warrants, will not be adjusted or provided for if we issue those securities or any securities convertible into or exchangeable for those securities, or securities carrying the right to purchase those securities or securities convertible into or exchangeable for those securities. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Holders of common stock warrants may have additional rights under the following circumstances: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">certain reclassifications, capital reorganizations or changes of the common stock;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">certain share exchanges, mergers, or similar transactions involving us that result in changes of the common stock; or</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">certain sales or dispositions to another entity of all or substantially all of our property and assets.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If one of the above transactions occurs and holders of our common stock are entitled to receive shares, securities or other property with respect to or in exchange for their securities, the holders of the common stock warrants then-outstanding, as applicable, will be entitled to receive upon exercise of their warrants the kind and amount of shares and other securities or property that they would have received upon the applicable transaction if they had exercised their warrants immediately before the transaction. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#Toc1">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="DESCRIPTIONOFRIGHTS">DESCRIPTION OF RIGHTS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following description, together with the additional information we include in any applicable prospectus supplement, summarizes the general features of the rights that we may offer under this prospectus. We may issue rights to our stockholders to purchase shares of our common stock and/or any of the other securities offered hereby. Each series of rights will be issued under a separate rights agreement to be entered into between us and a bank or trust company, as rights agent. When we issue rights, we will provide the specific terms of the rights and the applicable rights agreement in a prospectus supplement. Because the terms of any rights we offer under a prospectus supplement may differ from the terms we describe below, you should rely solely on information in the applicable prospectus supplement if that summary is different from the summary in this prospectus. We will incorporate by reference into the registration statement of which this prospectus is a part, the form of rights agreement that describes the terms of the series of rights we are offering before the issuance of the related series of rights. The applicable prospectus supplement relating to any rights will describe the terms of the offered rights, including, where applicable, the following: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">the date for determining the persons entitled to participate in the rights distribution;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">the exercise price for the rights;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">the aggregate number or amount of underlying securities purchasable upon exercise of the rights;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">the number of rights issued to each stockholder and the number of rights outstanding, if any;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">the extent to which the rights are transferable;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">the date on which the right to exercise the rights will commence and the date on which the right will expire;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">the extent to which the rights include an over-subscription privilege with respect to unsubscribed securities;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">anti-dilution provisions of the rights, if any; and</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">any other terms of the rights, including terms, procedures and limitations relating to the distribution, exchange and exercise of the rights.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Holders may exercise rights as described in the applicable prospectus supplement. Upon receipt of payment and the rights certificate properly completed and duly executed at the corporate trust office of the rights agent or any other office indicated in the prospectus supplement, we will, as soon as practicable, forward the securities purchasable upon exercise of the rights. If less than all of the rights issued in any rights offering are exercised, we may offer any unsubscribed securities directly to persons other than stockholders, to or through agents, underwriters or dealers or through a combination of such methods, including pursuant to standby underwriting arrangements, as described in the applicable prospectus supplement. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="DESCRIPTIONOFUNITS">DESCRIPTION OF UNITS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We may issue units comprising two or more securities described in this prospectus in any combination. For example, we might issue units consisting of a combination of common stock and warrants to purchase common stock. The following description sets forth certain general terms and provisions of the units that we may offer pursuant to this prospectus. The particular terms of the units and the extent, if any, to which the general terms and provisions may apply to the units so offered will be described in the applicable prospectus supplement. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Each unit will be issued so that the holder of the unit also is the holder of each security included in the unit. Thus, the unit will have the rights and obligations of a holder of each included security. Units will be issued pursuant to the terms of a unit agreement, which may provide that the securities included in the unit may not be held or transferred separately at any time or at any time before a specified date. A copy of the forms of the unit agreement and the unit certificate relating to any particular issue of units will be filed with the SEC each time we issue units, and you should read those documents for provisions that may be important to you. For more information on how you can obtain copies of the forms of the unit agreement and the related unit certificate, see &#8220;Where You Can Find More Information.&#8221; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#Toc1">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The prospectus supplement relating to any particular issuance of units will describe the terms of those units, including, to the extent applicable, the following: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">the designation and terms of the units and the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">any provision for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units; and</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">whether the units will be issued in fully registered or global form.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="PLANOFDISTRIBUTION">PLAN OF DISTRIBUTION</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We may sell the securities from time to time, by a variety of methods, including the following: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">on any national securities exchange or quotation service on which our securities may be listed at the time of sale, including the Nasdaq Capital Market;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">in the over-the-counter market;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">in transactions otherwise than on such exchange or in the over-the-counter market, which may include privately negotiated transactions and sales directly to one or more purchasers;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">through ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">through purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">through underwriters, broker-dealers, agents, in privately negotiated transactions, or any combination of these methods;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">a combination of any of these methods; or</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">by any other method permitted pursuant to applicable law.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The securities may be distributed from time to time in one or more transactions: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:justify;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">at a fixed price or prices, which may be changed;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">at market prices prevailing at the time of sale;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">at prices related to such prevailing market prices; or</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">at negotiated prices.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Offers to purchase the securities being offered by this prospectus may be solicited directly. Agents may also be designated to solicit offers to purchase the securities from time to time. Any agent involved in the offer or sale of our securities will be identified in a prospectus supplement. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#Toc1">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If a dealer is utilized in the sale of the securities being offered by this prospectus, the securities will be sold to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an underwriter is utilized in the sale of the securities being offered by this prospectus, an underwriting agreement will be executed with the underwriter at the time of sale and the name of any underwriter will be provided in the prospectus supplement that the underwriter will use to make resales of the securities to the public. In connection with the sale of the securities, we, or the purchasers of securities for whom the underwriter may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter may sell the securities to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters and/or commissions from the purchasers for which they may act as agent. Unless otherwise indicated in a prospectus supplement, an agent will be acting on a best efforts basis and a dealer will purchase securities as a principal, and may then resell the securities at varying prices to be determined by the dealer. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Any compensation paid to underwriters, dealers or agents in connection with the offering of the securities, and any discounts, concessions or commissions allowed by underwriters to participating dealers will be provided in the applicable prospectus supplement. Underwriters, dealers and agents participating in the distribution of the securities may be deemed to be underwriters within the meaning of the Securities Act, and any discounts and commissions received by them and any profit realized by them on resale of the securities may be deemed to be underwriting discounts and commissions. In compliance with the guidelines of the Financial Industry Regulatory Authority, Inc., or FINRA, the maximum amount of underwriting compensation, including underwriting discounts and commissions, to be paid in connection with any offering of securities pursuant to this prospectus may not exceed 8% of the aggregate principal amount of securities offered. We may enter into agreements to indemnify underwriters, dealers and agents against civil liabilities, including liabilities under the Securities Act, or to contribute to payments they may be required to make in respect thereof and to reimburse those persons for certain expenses. The securities may or may not be listed on a national securities exchange. To facilitate the offering of securities, certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price of the securities. This may include over-allotments or short sales of the securities, which involve the sale by persons participating in the offering of more securities than were sold to them. In these circumstances, these persons would cover such over-allotments or short positions by making purchases in the open market or by exercising their over-allotment option, if any. In addition, these persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the open market or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the open market. These transactions may be discontinued at any time. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If indicated in the applicable prospectus supplement, underwriters or other persons acting as agents may be authorized to solicit offers by institutions or other suitable purchasers to purchase the securities at the public offering price set forth in the prospectus supplement, pursuant to delayed delivery contracts providing for payment and delivery on the date or dates stated in the prospectus supplement. These purchasers may include, among others, commercial and savings banks, insurance companies, pension funds, investment companies and educational and charitable institutions. Delayed delivery contracts will be subject to the condition that the purchase of the securities covered by the delayed delivery contracts will not at the time of delivery be prohibited under the laws of any jurisdiction in the United States to which the purchaser is subject. The underwriters and agents will not have any responsibility with respect to the validity or performance of these contracts. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We may engage in at-the-market offerings into an existing trading market in accordance with rule 415(a)(4) under the Securities Act. In addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by us, or borrowed from us or others to settle those sales or to close out any related open borrowings of common stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of our common stock. In addition, we may loan or pledge securities to a financial institution or other third party that in turn may sell the securities using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering of other securities. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#Toc1">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The underwriters, dealers and agents may engage in transactions with us, or perform services for us, in the ordinary course of business for which they receive compensation. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="LEGALMATTERS">LEGAL MATTERS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unless otherwise indicated in the applicable prospectus supplement, certain legal matters in connection with the offering and the validity of the securities offered by this prospectus, and any supplement thereto, will be passed upon by Sichenzia Ross Ference Carmel LLP. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="EXPERTS">EXPERTS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The financial statements of Lexaria Bioscience Corp. incorporated in this prospectus by reference to the Annual Report on Form 10-K for the year ended August 31, 2024 have been so incorporated in reliance on the report of MaloneBailey, LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#Toc1">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="lxrp_s3img2.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Lexaria Bioscience Corp. </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>$50,000,000 </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Common Stock </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Warrants </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Rights </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Units </strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#Toc1">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PART II </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>INFORMATION NOT REQUIRED IN THE PROSPECTUS </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 14.</strong> <strong>OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION </strong>&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table sets forth the costs and expenses payable by us in connection with this offering, other than underwriting commissions and discounts, all of which are estimated except for the SEC registration fee.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">SEC registration fee</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,655.00</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px">Printing</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">*</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Legal fees and expenses</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">*</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px">Accounting fees and expenses</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">*</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Warrant Agent Fees and Expenses</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">*</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px">Miscellaneous</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">*</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Total</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">*</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="text-align:justify;margin:0px">*</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be estimated at this time. The applicable prospectus supplement will set forth the estimated amount of expenses of any offering of securities.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 15.</strong> <strong>INDEMNIFICATION OF DIRECTORS AND OFFICERS </strong>&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Indemnification of Directors and Officers</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The NRS empower us to indemnify our directors and officers against expenses relating to certain actions, suits or proceedings as provided for therein. In order for such indemnification to be available, the applicable director or officer must not have acted in a manner that constituted a breach of his or her fiduciary duties and involved intentional misconduct, fraud or a knowing violation of law, or must have acted in good faith and reasonably believed that his or her conduct was in, or not opposed to, our best interests. In the event of a criminal action, the applicable director or officer must not have had reasonable cause to believe his or her conduct was unlawful.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to our Articles of Incorporation, we may indemnify each of our present and future directors, officers, employees or agents who becomes a party or is threatened to be made a party to any suit or proceeding, whether pending, completed or merely threatened, and whether said suit or proceeding is civil, criminal, administrative, investigative, or otherwise, except an action by or in the right of the Company, by reason of the fact that he is or was a director, officer, employee, or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust, or other enterprise, against expenses, including, but not limited to, attorneys&#8217; fees, judgments, fines, and amounts paid in settlement actually and reasonably incurred by him in connection with the action, suit, proceeding or settlement, provided such person acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interest of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The expenses of directors, officers, employees or agents of the Company incurred in defending a civil or criminal action, suit, or proceeding may be paid by the Company as they are incurred and in advance of the final disposition of the action, suit, or proceeding, if and only if the director, officer, employee or agent undertakes to repay said expenses to the Company if it is ultimately determined by a court of competent jurisdiction, after exhaustion of all appeals therefrom, that he is not entitled to be indemnified by the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">No indemnification shall be applied, and any advancement of expenses to or on behalf of any director, officer, employee or agent must be returned to the Company, if a final adjudication establishes that the person&#8217;s acts or omissions involved a breach of any fiduciary duties, where applicable, intentional misconduct, fraud or a knowing violation of the law which was material to the cause of action.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#Toc1">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The NRS further provides that a corporation may purchase and maintain insurance or make other financial arrangements on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise for any liability asserted against him and liability and expenses incurred by him in his capacity as a director, officer, employee or agent, or arising out of his status as such, whether or not the corporation has the authority to indemnify him against such liability and expenses. We have secured a directors&#8217; and officers&#8217; liability insurance policy. We expect that we will continue to maintain such a policy.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Disclosure of Commission Position on Indemnification for Securities Act Liabilities</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Insofar as indemnification for liabilities under the Securities Act may be permitted to officers, directors or persons controlling the Company pursuant to the foregoing provisions, the Company has been informed that is it is the opinion of the SEC that such indemnification is against public policy as expressed in such Securities Act and is, therefore, unenforceable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 16.</strong> <strong>EXHIBITS </strong>&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A list of exhibits included as part of this registration statement is set forth in the Exhibit Index and is incorporated herein by reference. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 17.</strong> <strong>UNDERTAKINGS </strong>&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(a) The undersigned registrant hereby undertakes:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(i) To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>provided, however</em>, Paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the registration statement is on Form S-3 or Form F-3 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#Toc1">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(A) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(B) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; or</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(5) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(b) The registrant hereby undertakes that for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&#8217;s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(d) The registrant hereby undertakes that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(2) For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#Toc1">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SIGNATURES </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Kelowna, British Columbia, on the&nbsp;22&nbsp;day of January, 2025.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="margin:0px"><strong>LEXARIA BIOSCIENCE CORP.</strong></p></td> <td></td></tr> <tr style="height:15px"> <td style="width:50%;"></td> <td style="width:5%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:35%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:10%;"></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;"> <p style="margin:0px">/<em>s</em>/ <em>Richard Christopher </em></p></td> <td></td></tr> <tr style="height:15px"> <td></td> <td> <p style="margin:0px">Name: </p></td> <td style="vertical-align:top;"> <p style="margin:0px">Richard Christopher </p></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="margin:0px">Title:</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Chief Executive Officer</p></td> <td></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>POWER OF ATTORNEY </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Richard Christopher, his or her true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for such person and in his or her name, place and stead, in any and all capacities, in connection with the Registrant&#8217;s Registration Statement on Form S-3 under the Securities Act of 1933, as amended, or the Securities Act, any and all pre-effective and post-effective amendments to this Registration Statement, and any Registration Statement filed pursuant to Rule 413 or Rule 462 under the Securities Act, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys -in-fact and agents, and each of them singly, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the foregoing, as fully and to all intents and purposes as each might or could do in person hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue of this Power of Attorney. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;vertical-align:bottom;"> <p style="text-align:center;margin:0px"><strong>Signature</strong></p></td> <td style="width:2%;"> <p style="text-align:center;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="text-align:center;margin:0px"><strong>Title</strong></p></td> <td style="width:2%;"> <p style="text-align:center;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:20%;vertical-align:top;"> <p style="text-align:center;margin:0px"><strong>Date</strong></p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="text-align:center;margin:0px">/s/ <em>Richard Christopher </em></p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Chief Executive Officer &amp; Director</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">January&nbsp;22, 2025</p></td></tr> <tr style="height:15px"> <td style="vertical-align:bottom;"> <p style="text-align:center;margin:0px">Richard Christopher </p></td> <td></td> <td> <p style="text-align:justify;margin:0px">(Principal Executive Officer)</p></td> <td></td> <td></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="text-align:center;margin:0px">/s/ <em>Michael Shankman</em></p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Chief Financial Officer </p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">January 22, 2025</p></td></tr> <tr style="height:15px"> <td style="vertical-align:bottom;"> <p style="text-align:center;margin:0px">Michael Shankman</p></td> <td></td> <td> <p style="text-align:justify;margin:0px">(Principal Financial Officer and Principal Accounting Officer)</p></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td> <td></td> <td> <p style="text-align:center;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="text-align:center;margin:0px">/s/ <em>John Docherty</em></p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:justify;margin:0px">President, Chief Science Officer and Director</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">January 22, 2025</p></td></tr> <tr style="height:15px"> <td style="vertical-align:bottom;"> <p style="text-align:center;margin:0px">John Docherty</p></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td> <td></td> <td> <p style="text-align:center;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="text-align:center;margin:0px">/s/ <em>Christopher Bunka</em></p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Chairman and Director</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">January 22, 2025</p></td></tr> <tr style="height:15px"> <td style="vertical-align:bottom;"> <p style="text-align:center;margin:0px">Christopher Bunka</p></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:center;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="text-align:center;margin:0px">/s/ <em>William Edward McKechnie</em></p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Director</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">January 22, 2025</p></td></tr> <tr style="height:15px"> <td style="vertical-align:bottom;"> <p style="text-align:center;margin:0px">William Edward McKechnie</p></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td> <td></td> <td> <p style="text-align:center;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="text-align:center;margin:0px">/s/ <em>Nicholas Baxter</em></p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Director</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">January 22, 2025</p></td></tr> <tr style="height:15px"> <td style="vertical-align:bottom;"> <p style="text-align:center;margin:0px">Nicholas Baxter</p></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td> <td></td> <td> <p style="text-align:center;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="text-align:center;margin:0px">/s/ <em>Albert Reese Jr</em>.</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Director </p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">January 22, 2025</p></td></tr> <tr style="height:15px"> <td style="vertical-align:bottom;"> <p style="text-align:center;margin:0px">Albert Reese Jr.</p></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td> <p style="text-align:center;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="text-align:center;margin:0px">/s/ <em>Bal Bhullar</em></p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Director </p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">January 22, 2025</p></td></tr> <tr style="height:15px"> <td style="vertical-align:bottom;"> <p style="text-align:center;margin:0px">Bal Bhullar</p></td> <td></td> <td></td> <td></td> <td></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#Toc1">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EXHIBIT INDEX </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:9%;"> <p style="text-align:justify;margin:0px"><strong>Exhibit </strong></p> <p style="text-align:justify;margin:0px"><strong>Number</strong></p></td> <td style="width:1%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="text-align:justify;margin:0px"><strong>Description</strong></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="text-align:center;margin:0px">1.1(1)</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">Form of Underwriting Agreement</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="text-align:center;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1348362/000164033421000109/lxrp_ex31.htm">3.1</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1348362/000164033421000109/lxrp_ex31.htm">Amended and Restated Articles of Incorporation (incorporated by reference as Exhibit 3.1 to our Current Report Form 8-K filed January 14, 2021)</a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="text-align:center;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1348362/000164033421000109/lxrp_ex32.htm">3.2</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1348362/000164033421000109/lxrp_ex32.htm">Second Amended and Restated Bylaws (incorporated by reference as Exhibit 3.2 to our Current Report on Form 8-K filed January 14, 2021)</a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="text-align:center;margin:0px">4.1 (1)</p></td> <td> <p style="text-align:center;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">Form of Common Stock Warrant Agreement and Warrant Certificate.</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="text-align:center;margin:0px">4.2 (1)</p></td> <td> <p style="text-align:center;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">Form of Rights Agreement.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="text-align:center;margin:0px">4.3 (1)</p></td> <td> <p style="text-align:center;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">Form of Unit Agreement and Unit Certificate.</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="text-align:center;margin:0px"><a href="lxrp_ex51.htm">5.1</a></p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px"><a href="lxrp_ex51.htm">Opinion of Sichenzia Ross Ference Carmel LLP (filed herewith). </a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="text-align:center;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1348362/000164033424001787/lxrp_ex211.htm">21.1</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1348362/000164033424001787/lxrp_ex211.htm">List of Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to Form 10-K filed November 26, 2024 )</a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="text-align:center;margin:0px"><a href="lxrp_ex231.htm">23.1</a></p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px"><a href="lxrp_ex231.htm">Consent of MaloneBailey, LLP</a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="text-align:center;margin:0px"><a href="lxrp_ex51.htm">23.2</a></p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px"><a href="lxrp_ex51.htm">Consent of Sichenzia Ross Ference Carmel LLP (Included in Exhibit 5.1)</a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="text-align:center;margin:0px">24.1</p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px">Power of Attorney (included on signature page). </p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="text-align:center;margin:0px"><a href="lxrp_ex107.htm">107</a></p></td> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="text-align:justify;margin:0px"><a href="lxrp_ex107.htm">Filing Fee Table (filed herewith)</a></p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="text-align:justify;margin:0px">(1)</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px">To be filed either by amendment or as an exhibit to a report filed under the Exchange Act, and incorporated herein by reference.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>lxrp_ex51.htm
<DESCRIPTION>OPINION
<TEXT>
<html><head><title>lxrp_ex51.htm</title><!--Document created using EDGARMaster--></head><body style="COLOR: #000000; TEXT-ALIGN: justify; FONT: 10pt Times New Roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 5.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><img src="lxrp_ex51img1.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 279pt; text-align:right;">January 22, 2025</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Lexaria Bioscience Corp.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">#100 - 740 McCurdy Road</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Kelowna, British Columbia V1X 2P7</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Re<em>:</em></strong></p></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><strong><em>Lexaria Bioscience Corp. Registration Statement on Form S-3</em></strong></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Ladies and Gentlemen:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">We have acted as counsel to Lexaria Bioscience Corp., a Nevada corporation (the &#8220;<u>Company</u>&#8221;), in connection with the preparation of the Registration Statement on Form S-3 (the &#8220;<u>Registration Statement</u>&#8221;) filed with the Securities and Exchange Commission (the &#8220;<u>Commission</u>&#8221;) on January 22, 2025 under the Securities Act of 1933, as amended (the &#8220;<u>Securities Act</u>&#8221;). The Registration Statement relates to the Company&#8217;s proposed offer and sale from time to time, pursuant to Rule 415 of the General Rules and Regulations of the Commission promulgated under the Securities Act, of an aggregate of up to $50,000,000 of the following securities:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(i) </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;<u>Common Stock</u>&#8221;);</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(ii) </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">warrants to purchase Common Stock (individually or collectively, the &#8220;<u>Warrants</u>&#8221;) to be issued pursuant to one or more warrant agreements (each, a &#8220;<u>Warrant Agreement</u>&#8221;) between the Company and a warrant agent to be appointed prior to the issuance of Warrants;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(iii) </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">rights to purchase any Company Securities (as defined below) (individually or collectively, the &#8220;<u>Rights</u>&#8221;) to be issued pursuant to one or more rights agreements (each, a &#8220;<u>Rights Agreement</u>&#8221;) between the Company and a rights agent to be appointed prior to the issuance of Rights; and</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(iv) </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">units consisting of two or more securities of Common Stock, Warrants, and/or Rights (the &#8220;<u>Units</u>&#8221; and together with the Common Stock, Warrants and Rights, the &#8220;<u>Company Securities</u>&#8221;) to be issued pursuant to one or more unit agreements (each, a &#8220;<u>Unit Agreement</u>&#8221; and, together with the Warrant Agreements and Rights Agreements, the &#8220;<u>Agreements</u>&#8221;) between the Company and a unit agent to be appointed prior to the issuance of Units.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In our capacity as counsel, we have examined originals or copies of those corporate and other records and documents we considered appropriate including, without limitation: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(i) </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">the Registration Statement;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(ii) </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">the Articles of Incorporation of the Company, including all amendments thereto, as presently in effect (the &#8220;<u>Company&#8217;s Articles of Incorporation</u>&#8221;);</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(iii) </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">the Amended and Restated Bylaws of the Company, as presently in effect (the &#8220;<u>Company&#8217;s Bylaws</u>&#8221; and, together with the Company&#8217;s Articles of Incorporation, the &#8220;<u>Organizational Documents</u>&#8221;); and</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(iv) </p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">resolutions of the board of directors of the Company (the &#8220;Board of Directors&#8221;) relating to the registration of the Company Securities, as applicable, and related matters.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:center;"><font style="color:#1d1060">1185 AVENUE OF THE AMERICAS | 31ST FLOOR | NEW YORK, NY | 10036 </font></p> <p style="MARGIN: 0px; text-align:center;"><font style="color:#1d1060">T (212) 930-9700 | F (212) 930-9725 |</font> <font style="color:#44c1f5">WWW.SRFC.LAW</font></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In our examination, we have assumed the legal capacity of all natural persons, the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, conformed or photostatic copies and the authenticity of the originals of such latter documents. We have also assumed that New York law will be chosen to govern the Warrant Agreements, the Rights Agreements and the Unit Agreements and that such choice is a valid and legal provision. To the extent the Company&#8217;s obligations depend on the enforceability of any agreement against the other parties to such agreement, we have assumed that such agreement is enforceable against such other parties. As to any facts material to the opinions expressed herein which were not independently established or verified, we have relied upon oral or written statements and representations of officers and other representatives of the Company. In addition, we have obtained and relied upon those certificates of public officials we considered appropriate.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In connection with each of the opinions expressed below, we have assumed that, at or prior to the time of delivery of any Company Security, (i) the Registration Statement has been declared effective and such effectiveness has not been terminated or rescinded, (ii) a prospectus supplement, to the extent required by applicable law and relevant rules and regulations of the Commission, will be timely filed with the Commission describing each class or series of Company Securities offered thereby and any other matters required thereby and will comply with applicable law, (iii) the definitive terms of the issuance and sale of each class or series of Company Securities will have been duly established in accordance with the authorizing resolutions adopted by the Company&#8217;s Board of Directors (or an authorized committee thereof) and in conformity with the applicable Organizational Documents and applicable law (including (A) the due reservation of any shares of Common Stock, for issuance upon exercise, conversion or exchange of any Company Securities or pursuant to the existing Rights Agreement of the Company, as amended, for Common Stock (a &#8220;<u>Convertible Security</u>&#8221;), and (B) the execution (in the case of certificated Company Securities), delivery and performance of the Company Securities and any related documentation referred to in paragraphs 1 through 4 below shall have been duly completed and shall remain in full force and effect), (iv) upon issuance of any Common Stock, including upon exercise, conversion or exchange of any Convertible Security, the total number of shares of Common Stock issued and outstanding will not exceed the total number of shares of Common Stock that the Company is then authorized to issue under the Company&#8217;s Articles of Incorporation and other relevant documents; (v) all Company Securities will be issued and sold in the manner contemplated by the Registration Statement and any applicable prospectus supplement; and (vi) there has not occurred any change in law or further action by the Board of Directors, in any case affecting the validity or enforceability of such security. We have also assumed that none of the terms of any Company Security to be established after the date hereof, nor the issuance and delivery of such Company Security, nor the compliance by the Company with the terms of such Company Security will violate any applicable law or public policy or result in a violation of any provision of any instrument or agreement then binding upon the Company or any restriction imposed by any court or governmental body having jurisdiction over the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">On the basis of such examination, our reliance upon the assumptions in this opinion and our consideration of those questions of law we considered relevant, and subject to the limitations and qualifications in this opinion, we are of the opinion that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">1.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">When an issuance of Common Stock has been duly authorized by all necessary corporate action of the Company, upon issuance, delivery and payment therefor in an amount not less than the par value thereof and in the manner contemplated by the Registration Statement and/or the prospectus and applicable prospectus supplement(s) and by such corporate action, such shares of Common Stock will be validly issued, fully paid and nonassessable.</p></td></tr> <tr style="height:15px"> <td></td> <td></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">With respect to any Warrants offered under the Registration Statement, when (i) the Common Stock relating to such Warrants have been duly authorized for issuance, (ii) the applicable Warrant Agreement has been duly authorized, executed and delivered by each party thereto, and (iii) the Warrants have been duly authorized, executed, issued and delivered in accordance with the terms of the applicable Warrant Agreement and the applicable underwriting or other agreement, such Warrants will be legally valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to creditors&#8217; rights generally (including, without limitation, fraudulent conveyance laws) or by general principles of equity including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing and the possible unavailability of specific performance or injunctive relief, regardless of whether considered in a proceeding at law or in equity.</p></td></tr> <tr style="height:15px"> <td></td> <td></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">3.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">With respect to any Rights offered under the Registration Statement, when (i) the Company Securities relating to such Rights have been duly authorized for issuance, (ii) the applicable Rights Agreement has been duly authorized, executed and delivered by each party thereto, and (iii) the Rights have been duly authorized, executed, issued and delivered in accordance with the terms of the applicable Rights Agreement and the applicable underwriting or other agreement, such Rights will be legally valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to creditors&#8217; rights generally (including, without limitation, fraudulent conveyance laws) or by general principles of equity including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing and the possible unavailability of specific performance or injunctive relief, regardless of whether considered in a proceeding at law or in equity.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">4.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">With respect to any Units offered under the Registration Statement, when (i) the Company Securities relating to such Units have been duly authorized for issuance, (ii) the applicable Unit Agreement has been duly authorized, executed and delivered by each party thereto, and (iii) the Units have been duly authorized, executed, issued and delivered in accordance with the terms of the applicable Unit Agreement and the applicable underwriting or other agreement, such Units will be legally valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to creditors&#8217; rights generally (including, without limitation, fraudulent conveyance laws) or by general principles of equity including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing and the possible unavailability of specific performance or injunctive relief, regardless of whether considered in a proceeding at law or in equity.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:center;"><font style="color:#1d1060">1185 AVENUE OF THE AMERICAS | 31ST FLOOR | NEW YORK, NY | 10036 </font></p> <p style="MARGIN: 0px; text-align:center;"><font style="color:#1d1060">T (212) 930-9700 | F (212) 930-9725 |</font> <font style="color:#44c1f5">WWW.SRFC.LAW</font></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The law covered by this opinion is limited to the present law of the State of New York and the current Nevada Revised Statutes. The law covered in paragraphs 2, 3, and 4 of this opinion as to the enforceability of the Warrants, the Rights and the Unit Agreements is limited to the present law of the State of New York. We express no opinion as to the laws of any other jurisdiction and no opinion regarding the statutes, administrative decisions, rules, regulations or requirements of any county, municipality, subdivision or local authority of any jurisdiction.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">This opinion is being furnished in accordance with the requirements of Item 601(b)(5) of Regulation S-K promulgated under the Securities Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement, the prospectus included in the Registration Statement or any prospectus supplement, other than as expressly stated herein with respect to the Company Securities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">We hereby consent to the use of this opinion as an exhibit to the Registration Statement and to the reference to this firm under the heading &#8220;Legal Matters&#8221; in the prospectus constituting part of the Registration Statement. This opinion is expressly limited to the matters set forth above, and we render no opinion, whether by implication or otherwise, as to any other matters. This letter speaks only as of the effectiveness date of the Registration Statement and we assume no obligation to update or supplement this opinion to reflect any facts or circumstances that arise after the date of this opinion and come to our attention, or any future changes in laws.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td>&nbsp;</td> <td> <p style="MARGIN: 0px; text-align:justify;">Very truly yours,</p></td> <td></td></tr> <tr style="height:15px"> <td style="width:47%;">&nbsp;</td> <td style="width:30%;">&nbsp;</td> <td style="width:15%;">&nbsp;</td></tr> <tr style="height:15px"> <td></td> <td style="BORDER-BOTTOM: black 1px solid;"> <p style="MARGIN: 0px; text-align:justify;">/s/ Sichenzia Ross Ference Carmel LLP</p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td>Sichenzia Ross Ference Carmel LLP</td> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:center;"><font style="color:#1d1060">1185 AVENUE OF THE AMERICAS | 31ST FLOOR | NEW YORK, NY | 10036</font></p> <p style="MARGIN: 0px; text-align:center;"><font style="color:#1d1060">T (212) 930-9700 | F (212) 930-9725 |</font> <font style="color:#44c1f5">WWW.SRFC.LAW</font></p> <p style="MARGIN: 0px; text-align:center;"><font style="color:#44c1f5"></font>&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>lxrp_ex231.htm
<DESCRIPTION>CONSENT
<TEXT>
<html><head><title>lxrp_ex231.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="MARGIN: 0px; text-align:right;"><strong>EXHIBIT 23.1</strong></p> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="MARGIN: 0px; text-align:center;"><strong>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</strong></p> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;">We consent to the incorporation by reference in this Registration Statement on Form S-3 of our report dated November 26, 2024 with respect to the audited consolidated financial statements of Lexaria Bioscience Corp. for the year ended August 31, 2024.</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;">We also consent to the references to us under the heading &#8220;Experts&#8221; in such Registration Statement.</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ MaloneBailey, LLP</em></p> <p style="MARGIN: 0px; text-align:justify;">www.malonebailey.com</p> <p style="MARGIN: 0px; text-align:justify;">Houston, Texas</p> <p style="MARGIN: 0px; text-align:justify;">January 22, 2025</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>lxrp_ex107.htm
<DESCRIPTION>FEE TABLE
<TEXT>
<html><head><title>lxrp_ex107.htm</title><!--Document created using EDGARMaster--></head><body style="COLOR: #000000; TEXT-ALIGN: justify; FONT: 10pt Times New Roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="MARGIN: 0px; text-align:right;"><strong>EXHIBIT 107</strong></p> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="MARGIN: 0px; text-align:center;"><strong>Calculation of Filing Fee Tables</strong></p> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="MARGIN: 0px; text-align:center;"><strong>Form S-3</strong></p> <p style="MARGIN: 0px; text-align:center;">(Form Type)</p> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="MARGIN: 0px; text-align:center;"><strong>Lexaria Bioscience Corp.</strong></p> <p style="MARGIN: 0px; text-align:center;">(Exact Name of Registrant as Specified in Its Charter)</p> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="MARGIN: 0px; text-align:center;"><u id="del_u6ef3d159-f56f-49ec-a830-327e64004804">Table 1: Newly Registered and Carry Forward Securities</u></p> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;"> <table style="border-spacing:0;width:100%;text-align:left;font:10pt times new roman" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;">Security </p> <p style="margin:0px">Type</p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;">Security </p> <p style="margin:0px">Class </p> <p style="margin:0px">Title</p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;">Fee </p> <p style="margin:0px">Calculation </p> <p style="margin:0px">or Carry Forward Rule</p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;">Amount </p> <p style="margin:0px">Registered </p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;">Proposed </p> <p style="margin:0px">Maximum </p> <p style="margin:0px">Offering </p> <p style="margin:0px">Price per </p> <p style="margin:0px">Unit </p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;">Maximum </p> <p style="margin:0px">Aggregate </p> <p style="margin:0px">Offering </p> <p style="margin:0px">Price </p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;">Fee </p> <p style="margin:0px">Rate</p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;">Amount of Registration Fee</p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;">Carry Forward Form Type</p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;">Carry Forward </p> <p style="margin:0px">File </p> <p style="margin:0px">Number</p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;">Carry Forward </p> <p style="margin:0px">Initial </p> <p style="margin:0px">Effective </p> <p style="margin:0px">Date</p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;">Filing Fee </p> <p style="margin:0px">Previously </p> <p style="margin:0px">Paid in </p> <p style="margin:0px">Connection </p> <p style="margin:0px">with </p> <p style="margin:0px">Unsold </p> <p style="margin:0px">Securities </p> <p style="margin:0px">to be </p> <p style="margin:0px">Carried </p> <p style="margin:0px">Forward</p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="48"> <p style="MARGIN: 0px; text-align:center;"><strong>Newly Registered Securities</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Fees to be Paid</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:center;">Equity</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:center;">Common Stock, par value $0.001 per share</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:center;">Rule 457(o)</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">(1</td> <td style="vertical-align:bottom;white-space: nowrap;">)</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">(2</td> <td style="vertical-align:bottom;white-space: nowrap;">)</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">(2</td> <td style="vertical-align:bottom;white-space: nowrap;">)</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">0.00015310</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:center;">Equity</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:center;">Warrants</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:center;">Rule 457(o)</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">(1</td> <td style="vertical-align:bottom;white-space: nowrap;">)</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">(2</td> <td style="vertical-align:bottom;white-space: nowrap;">)</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">(2</td> <td style="vertical-align:bottom;white-space: nowrap;">)</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">0.00015310</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:center;">Equity</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:center;">Rights</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:center;">Rule 457(o)</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">(1</td> <td style="vertical-align:bottom;white-space: nowrap;">)</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">(2</td> <td style="vertical-align:bottom;white-space: nowrap;">)</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">(2</td> <td style="vertical-align:bottom;white-space: nowrap;">)</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">0.00015310</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:center;">Other</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:center;">Units</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:center;">Rule 457(o)</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">(1</td> <td style="vertical-align:bottom;white-space: nowrap;">)</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">(2</td> <td style="vertical-align:bottom;white-space: nowrap;">)</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">(2</td> <td style="vertical-align:bottom;white-space: nowrap;">)</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">0.00015310</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">--</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="width:6%;vertical-align:top;"> <p style="margin:0px">Fees Previously Paid</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:4%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:4%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:4%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:4%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:4%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:4%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:4%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:4%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:4%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:4%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td colspan="49" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong>Carry Forward Securities</strong></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Carry Forward Securities</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="17" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px; text-align:left;"><strong>Total Offering Amounts</strong>&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">50,000,000</td> <td style="vertical-align:bottom;white-space: nowrap;">(3)</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">0.00015310</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">7,655</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="17" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px; text-align:left;"><strong>Total Fees Previously Paid</strong>&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="17" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Total Fee Offsets</strong>&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="17" style="vertical-align:bottom;text-align:right;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Net Fee Due</strong>&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="vertical-align:bottom;text-align:right;">7,655</td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table></p> <p style="MARGIN: 0px; text-align:justify;">&nbsp; <p style="MARGIN: 0px; text-align:justify;"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(1)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">An indeterminate amount of the securities of each identified class is being registered as may from time to time be offered hereunder at indeterminate prices, along with an indeterminate number of securities that may be issued upon exercise, settlement, exchange or conversion of securities offered or sold hereunder. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or pursuant to anti-dilution provisions of any of the securities. Separate consideration may or may not be received for securities that are issuable upon conversion, exercise or exchange of other securities.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(2)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The proposed maximum offering price per security and proposed maximum aggregate offering price per class of security will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of security pursuant to the Instructions to the Calculation of Filing Fee Tables and Related Disclosure of Form S-3 under the Securities Act</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(3)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The proposed maximum aggregate offering price is estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act. Subject to Rule 462(b) under the Securities Act, the aggregate maximum offering price of all securities issued by the registrant pursuant to this registration statement will not exceed $50,000,000.00.</p></td></tr></table></p> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>lxrp_ex51img1.jpg
<TEXT>
begin 644 lxrp_ex51img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" !/ +T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Z(^,6L>)-
M!^$&OZQX4W+JUK"KQR*@=HDWKYC@$$$JFX_A7Q-_PO[XP8_Y'BX_\!X/_B*_
M1=E612K*&4C!!&017SSX[_98\(>(9I]0\*7DGAJ^D)8P*OFVK-_N9!3_ ("<
M#TKTL#7H4[QK1^=KFD)16Y\W_P#"_P#XQ?\ 0[W'_@/!_P#$5[_^S)\1/&?C
M;5?$\/BS7I-3CM(;=H!)%&FPLSAONJ.N!UKY_P#%_P !OB9X.:26ZT!]4LDS
M_I>F$W"8]2H&]?Q6O5_V.,C7_&2MG<MO:@@\$'=+P:]/%JA+#RG32^5NYK+E
MY=#Z\N+BWM8&GNIXX(EZO(P51^)JG_PD&@_]!FQ_\"4_QKS']I8!OV=_$0(R
M-]MU_P"OB.OSU\I/[B_E7FX3 ?6(.?-;6QE&',KGZMPZQI-U,(;;5+2:4]$C
MF5F/X U5\0:7?:MH%Q8Z;K=UHUVXS#>6JHSQ-V.UP0P]0>OJ.M?EC'F&5982
M8Y$.5=#M93Z@CI7Z!_LY>,M8\9?"2&XURX>ZOM/NY+%KF0Y>95"LK,>[8< G
MOC)Y-&*P#PT5)2N$H<NIZ#X+L_$NG^#K"R\7:@FI:W"KI<W<8 68[VVL  ,9
M7;QCBO%?B1\4/$2_'"#X;6/BVR\":8ELDTNM75NLK3LR[@J[_D4=@3CD-ST%
M?1U?/OQ,\2>#7\;2:'\6OA?<-H<<?^@^(DC>Y63."5S$H>/J>,DY'3!!KCH6
ME-MJ_P!WX)[DK<Z?P1;_ !1L_%2"^\<:+XU\(21$F]\M8;N-^<!1$"C#..IZ
M'MCGF_!7Q0UQOB)\7$\4:H;C0O"S-+;0K"BF&-6ER 0 6.$ Y)KS#PEH.CO\
M?O#E_P# B#7(?#\3AM:N)TE2T$>?F0&0 ME<C!SSM(Z$CI? OA>X\2?$GX]Z
M#,DEJFJF2VBGD0A<L\P# XY )!XKL<()OF[+I9K7MW+LC9\%7OQE^+N@3>-K
M/QU!X.TZ::1-,TZWTZ.X#!#C,COR1D$>^"<#@4[6?B1\4],_9\\4ZGX@TN3P
M_P"+-"NHK:._%L!#>H9E7S8U<$'(W X&.01C.!C_  I^*EG\*/!+?#_XBZ-J
MNE:MH\THA6.R>9;M&<N-C*,$Y8@'H1@YZXE\>^(O'OC3]F+QAJWB?PR-'BN+
MJW_LFS2%Q<M;_:$(:523SC'0#H3C!%%OWEK+ENK>GZBZGK6F>,UF^"]IKEQK
MMF=9?0UNW<O&&\\V^[.WIG=VQ[8KR"V^*GCM_P!CZY\>OK6?$4=\(EN_L\7"
M>>J8V;=OW21TK=TOX(_#.;X(V>N7'@Z!M9?05NGE+3!S/]GW%MN[KNYQC\*\
MTM+.^/[!-Y;_ &*X^TG4P?+\IM__ !](<XQFB$:3>FOO+=+S!6N>J^']'^+F
MO>'-*U9?CO:6\NHVL5P(/[#MF,9D0-M^\,D9QTKGOC#\2/B=X$^(VB:;X=OA
MJ=K9:+'J6IVYM8P+H)(RS2'@L@( SM/R]>U<]X3U;]G71],T&^U#P7J:Z_8P
MV\LUPNG71Q<HJEG'.#\X)Z8KT.Z:/7/VL?"VJ1VDKZ;>^$G?,T)"E79R%<$8
M!P>5-#Y8U&Y1NDGNDOR"^I8^(?Q8NIO@=I'CSP#JGV8W]_;0LQC21H@S$21,
MK @,",'].M==XN\-_$"\U>YU31OBPOAC2$A#&U?28)UAVK\[F1R#COSP*^8?
MBOX#\1?#/5Y_#>A037?@CQ#J$%_;Q)&TGV.>-^4X^Z<'&?XEQW6NT^/7Q N=
M;\;I\,6DU/1_"]NZ'6+^UM'FDN?E#B*,*/NX('H6//"\BHKW?9VL[N]KZ:?B
M@MV-OX/>*/BEXT^)-[<+XR?7/ >DR/#)?3Z;#;?VA)L("QA1D8)#9ST SRV*
MZG]GSQOXG\;:)XFN/$^I?;I;'56MH&\E(]D84''R@9^IYJ?X>_%'X9 Z1X!\
M(V.JV<>/(M8Y=,EB084L2SD=3@DD]2?>O&/AWXBU3P3\!?B1>6EC=C5KW66L
M]/186WF65 H8#'\(W-_P&DU[1235GHEI;KN&]S6\1_&SX@6?C"Z\<:;>HWPV
ML/$":*\"P(QG55S(X<KNP<,0<]2HKZQM;B*[M8KFWD5X95#HZ\AE(R"/PKYD
MB^!_Q2_X4^/A^?$OA]=(:+S&LVTYC*)2WF<RY^]OXW>GM7<?LX^)KW6/A1%H
MFN07%OJOA^4Z?*LZ,K&,?ZL\]<+\G_ *SQ$(RIWA;1VT[=&)VMH9</[2WAK2
M_B%KOA'QA9RZ5_9VH2VL.H1 RPR(K8!<#YD..N 1]*]GT7Q%H?B2P6_T'5K3
M4[4_\M;699%'L<'@^QK\X?BO_P EI\9?]A>Y_P#0S7-:5J^K:'?KJ&BZE=:9
M=KTFM)FB?\U(S7H?V9&I34H.SL:^SNM#]6C6?!I>FVNHW&H6^GVT-[<@+-<1
MQ*LDH&2 S 9;&3U]:^+_  %^U3XMT6XALO&T*Z_IN0K7,:B.[C'KQA9/H0"?
M6OLK0]:T_P 1:#9:WI-TMS8WL2S0RKT93_(]B.QKR:V&JX=^_LS&47'<Y'XS
M^$]8\<?"75_#6A+"VH79A,8GD\M/EE1CDX/8&ODS_AECXM?\^^D_^!W_ -C7
MVAXZ\8V/@+P3J'BS4K6XN;6QV;XK?;O;<ZH,;B!U8=Z\2_X;!\#_ /0L:_\
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M/$'B_2_$7Q1\:'Q2-)?S;+3H+-;6U1\@[G4$[N0/K@9XXJWK7PK\36_C6_\
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ME>DZ@K2Z5<)&-Q*$ =.:[\9*,I0Y7?W4>9@(2A&?,K>\SG/^$DU'TA_[X_\
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5<!DYQC%=K7*YR7NIDW84445F(__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>lxrp_s3img1.jpg
<TEXT>
begin 644 lxrp_s3img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" !@ +8# 2(  A$! Q$!_\0
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0SMSWKLZ*+A9"T444BC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>lxrp_s3img2.jpg
<TEXT>
begin 644 lxrp_s3img2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" !@ +8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[+HHHH 2B
MDJK'?6TET]JL@,J?>6LY5(QW'N7**;UIU4G?80E,>15'6HIITAA,DK!%49))
MZ5Y#XP\97=\9+'2Y6M[7[K2+P\O_ ,2OO652M&!S5ZRIQN==KOQ"\.Z$9([B
M[>>=.L-LOF,/Z5TVEZA;ZEI=OJ%OD17,:RKGT89KY5OOXJ^D? :NO@;1E;K]
MECS^0I4:O.<>&Q+J2L=911170>J%%%% !1110 4444 %%%% !1110 4444 %
M%%% %&\F6WM);ANB(6_K7G45Y)YWG^8WF;MV[_:KN?$;,N@7I7KY3?RKS"*>
MOG<=6E"1Z.&I<Z/4M(U%=0M=S<2I\KKZ&M,FO/?#M_Y&J)'NXE^1O_9:ZW5K
MTV6ERW"_? PGU[5=#&?N]3GKTN25CCO&FM/<2-IENW[A/]<R_P 9_NUYE??Q
MUTU]\VYF^]7,WW\=<SK.I,^<QR;T.?:UDU"^M[&W7=-<2+&O_ J^H]+MX['3
MK>UC^Y#&L:_0# _E7D'PU\-F]UF37;F/_1[;Y(-W\3]V_#I7MR+M4"O=PL;1
MN&!HN/O,EHHHKK/:"BO+-0\;:\GQ-G\-Z?IL5Q!;7%I&R+;RM(T<J[I)/-'[
MN/9UVM][%7H_B=X?:%KEK:^@M@8F$LR*JM#(9%CG^]]QFA9?[WW?E^:ERL#T
M6BO,3\6O#<FB1ZG;QWTT,LBQH%B579_)\Z1=K-]Z-?O#^]\M:-[\0M*M4U.9
MK&^:TTV&&2:Z**L;-*JM'&H9MVX[U_AXIV8'>T5YCJWQ,M8=&M[K2])O;F\G
M!D,<D:JMNJW"PLTGS=-S?+MW>M:_BOQC_P (OJ%HESI]Q<V$MI<7-Q-;KN:V
M6-HQN/S+\O[SZ\468';T5RNF>*M-U/Q'=:':QSF\M/,^T;EXAVR;5S_O9W+_
M +-=50 4444 %%%% #:6J%]J5EI=F]U?74=O GWI)6VJ/Q-8\'C;PS=OY=OK
MEE*?19US_.@TC3E):(U=4A^TV$\/]]"OYBO%8I67Y6^\ORU[8;J.:([6!!KQ
MWQ19MIOB:<* L4[>;'_P+[W_ (]7SF94N;5'JX%\LN61:L[KR[J&1?O+(K5W
M'B2<_9((1U.7_(5YG:R^9-&J_>9E6O1/$18O;HHR3&>*\RC&7+8,:ES'#WW\
M54--T&ZU_5%M8,K"O^MF'W8U_P#BJ["S\)W^IN#<[K6W_B+?>;Z+VKN]-TNT
MTNT6ULX1&B_F3ZFO5PF$DW=GSE6CSR'Z7IMKIEA#96L8CAB7:BCL*T::!7D]
MM\=/!5Y\3#\/(H]2.M?:Y+'<UK^Y\Q=V[YMWW?EKZ",;*R.B,5%61ZW1113*
M,^#3+&UU"]U"WMU2YOMGGR#K)M7:OY"N?7P+X56TOK$:# +6_96N(6W,LFUM
MRKU^50W.T?+78447 Y67P=X=FMGMFTF)8FNI+YO)9HV-Q)GS)-RG=EMS9J[<
M>'=%NK;4+6XT^*2'4BOVE6'^MVJJK^2JOY5NT47 Y.[\$^%[Z*QCN])%PMB-
ML#2S2,P&Y7PS%MS?,JM\V?NU)KGA/0?$4MO)K6FI=M;;A'N9EPK;=R_*?F4[
M5^4^E=1BC%*[ YO2?#]MIFN:WK*,TUYJ\T<DS, -JHFV./\ X#S_ -]5TE%>
M2ZU\<_">@_$V'X>7UMJ#:Q--!"K1PJ8MTVW;\V[_ &J:NP/6J*2EH **** .
M=\6:+#X@\,7VDS-A;B(J&'\)['\Z^36M+K3-0GT^^A$5Q;/L=#T+5]HLH92*
M\S\>_#N#Q(GV^Q9;;5(EPLA'RR#^Z_M[UG.-UH>AA*T8.TSROPYXFU?1W065
MV3".L$G*'Z#M7HL]U9^--(VPD1:C!\RHQY4^A_V6Z5Y+/I^H:-?&QU2U>UG'
M0/T;_=;^*MS2;^>SNH[JV<))&<@GH0:\NHF_=D>M.--KG@=/X3TZXO/%$5K+
M$5^R-OF##[N/X?\ OJO:XXE"@[1D=\5B^'[BSU&RCU*WC"-,HW''S9'8_2H;
MS4KA_$%M%ILXF$7F)/ I^ZVWY=W^-;4</&*N>+B*DIRL=&LD1D:-64NO5>]3
M5Y\M]JGA\OOL9+J_NOG>38S1K_L[E^\U=!H.H:UJ$;R:E8):1C_5_>5F_"O0
MC&R.-Z.QT-?!^@?\GPM_V,5U_P"@R5]X5^?C:[IOAG]K;4=?UBX:VL++7;B2
M>18V;:OS+]U?F_BK6*N!^@=?-/Q@^.'B'0/','P]^'NGQ7NN-L$LI3SF5V^9
M8T3^]M^9MU=Q8_M%_"?4M1M=/M?$,LES=3+#$OV.8;F9MH_AKY5^*5G)IW[4
M6KC4M:G\-QW-\MPNK1*S-!&\:[9%V_-C^'C_ &J(QUU ]5\(_'[XA:!\1;/P
M?\6M'CMA>21Q^>L'E/!O.U&^7Y63=QFM3XV?$KXJ?"_QC:W5E)87?A>_96@W
MVOS*R_?A9MWWO[I_^)KS2'X=^$?%GCS2]-D^/*ZYK$@5K=YK1Y VUMWE^<TG
MWOO;5KUC]JCQCHNE^!8O!\UM!>:IJK":-9/^72-&_P!=_O?PK_P*G9<P'+:U
M^T)XX\7?$O3/#OPEAMS!=QQQJ;JV\QFD9=TC-_=6/_V5J]2^+GB+XM>%O#6B
MIX)TF'7+J7;!?7J0&219<87$*]%9OXOX:^;OV>_$UAX#^+8L/%6EK:2:M$MK
M%=7*;9+-F^:/[WW5D^7G_=KO?VD/B)XQTSXCZ=X+TGQ!/X?TEK:&66XMV:-I
M/,9E9F9?FVKM^ZM#BN:P%"T_:"^+G@GQA9:;\4-$A2UN"K3(]MY$JQ,VW>C+
M\K;:]#_:'^+7B_X>7/AI?"-Q:)%J,5P\S3P>9NV^7MV_]]&OEGXGVD-GKUK;
MP?$9_'FVVW-=EBRV[;O]6K%F_P!ZO8/VMO\ CS\ ?]>-Q_Z##3:28&QX3^)W
M[1'C#QAHXL?#UK8:/>!9O,NK)EMF@&W<_F?>_P"^?[U:_C;XF/I?[4%CX1_X
M0SPW=K)=V4?]I7%ENO%\Q5^99/[R[OEKZ"\&_P#(A>'O^P;;?^BUKY ^)G_)
M\.F_]A'3/_08ZE:L#VSXS>*OC!H.I:99_#GPVM_;7?RM=1P^?(LO]UA]U5V_
MQ-7FOA7]H+XD:'\1[/PG\4M+AB6ZFCMWQ!Y,UOYGW9/E^5EK(^-7Q"\7W7QS
M;P/#XNN/">A6[PP-/!(8POF*K&5V7D_>KRGQ!;PVOQATRWM_&K>,UCN[-?[5
M;<VYO,7Y59F;[O\ O5:@K:@?I31116(#?2FM@@[NE/[URGC;6K[0/"]S?:9I
MDVH78&U8XESC_:;_ &13*BKM(3Q$NA&T;^VOLOV?_IXV[?UKS:2/X=^:3;WL
MD7J(=Y'Z@UY/=ZUJ6L:B]YJUX]Q<%OFW_P /^RJ_PUJZ:LES,L=O')/(WW5C
M7<U9N"ENCW*,5&.K/=O">I^';2 Z?IVJ&4NY=4F.&R?3(%='<Z;,]_)?V=U'
M!*\>P?N5//J6ZUY-9>'?[)TTZUXF/V6TB^80=9'/\(]OI3K+QMK&O>*-/MHY
MFM+5ITVV\3?P[OXF_BZ5T0HZ''6IIN\3K_$;7%Q_H&@ZM/\ VEIZ[I;83'?(
MK<AO]IA5?P?XZNIM530]<)\Z3Y8I77:Q;^ZWO7FNK^(+O1/BO?7C2$207I8_
M[4?]W_OFOHU;>TEV7#6\;OC*N5&:<URH\^I'4M]:\2US]G'X8^(/$FH:SJ+Z
ME]NU"=KB98[[:OF-][:NVO;.<5XO+:6LH\83S>"9]<N5U&?%U$(]P^5=JJV[
MS/E_V5K.-S-NQ5L/V8_ACI6I6FI6G]JBXM9TFBWWGR[E;<O\-=CX]^%?@?XA
M6\,GBC3_ -_:C$=Y#)Y,T:_W=W]WV-1:DS-X#\)2&\^VLU[IVZY7_EM\R_-5
MG5+"WUSXEPZ;JD*W=A:Z7]J6WD^9/-:7;N*_Q<+3U)YSG/!_[/?PU\(:Q#K5
MCIMS?7<#>9 ]_<&986_O*OW=WO2Z]\!_A_XL\;7'BK6IM1U'46E61XVO28UV
M_=CV_P *_P"S6SH]K/';>,?#>DW+01VTK0V!9FQ;^9;HVU?]E6;_ (#4&@0Z
M/HNHZ5;WWA*71-593!#=861)GV\KYJ-\S-M)^>C4.<K>.O@C\/\ QYK46L>(
M(;B&]2(0>9:W'D^8JGY=W]XK5CQ9\&? _C+1-/L?$4-W<RZ=$((+_P"T;;G9
M_=:3^+\:N0Z1IWB+QUXC.N6L=_%:>1;6\<R[EA5H]S;1ZEF^]2>*+%=*^%-S
MI\=Y-<BW:)4EF;=)M^T+M5F_V?N_\!HNQWZG%S_LN?"/[);P26^H0^7GY_MQ
M5I?]X]ZZOQU\(_!?Q*32U\0&[D72HFA@^RW/E_*VW=N_[Y6I_'4,,WB[PK%=
M:.^LQ,+O=:JJMN_=KS\S*M:<-K:V?A+5VL?#YT'S()F:W*QJ6;R_O?NV9:-6
M'-J=%8V=KIFDV=C;MBWM(4AC+'^%5VKS7 :Y\%_!NM?$B'XA:C]N768)H9U9
M;G;$&BV[?E_X#6$+RYTCX97OAB_GDDCETE;O3)Y&^:2':N^)F_O1LW_?++7;
M>*+5=2\3^&=%OF\S3[AKB:X@8_+,8T&U6'\0RV<>U&P*9C^//@UX%^)%U#J>
MN6<POHX_+6[LYO+>1/[K?PL*YJ']FWX3VU_97EO'=PS6;(R[;X_.RMNW-ZM7
MJ6B^';'0[F\;36:&"Y*R?9%_U,3?Q,B_P[OZ5PO@?3M*NM+L)+KP.\\QGDW:
MD\<++N\YOF^]N_\ ':+L+L]>HHHJ"PIK*K###-.HH Q[KP_I-Z_FW6GV\K^L
MD2L?U%/@TFQLX]MM;1PCTC0+_*M3/O3>HZT[FBJ2[GSG\:O$3?\ "36>@QOB
MWM8?M$@_O.>@_P"^?_0JV/A+X6N)@?%&H1E$9=EFC#[P_BD_^)KM]3^&/AK6
MO&K^*-6CDO9S&B+;2-^Y&W^+;WKN8HXXD"HH '  [5T.K[MD;NM[MD>(?%/X
M;ZOK'BBSUK0(?.^V-';WB*?FC_A63_=Q][_=KV^WC$-O'$.B*!4W:EKG<KZ'
M+<2N*;PC>+-J)L?$U_96VHW#W$L,447RLW7:S+N'2NUHI)V(:N<W-X7T^71=
M,TF'S+>VTZ:WFAVGG]TP95-1:MX?_M#4H-5M-0GT[48%,(N(55M\;?P,K##+
MNPU=5FC-%V'*CEM.\.PZ;IMW9K=74D]ZS/<7A?;-)(R[=VY?N]MN/NXJ"'PO
M.^HV5UJNO7NJBQD\RVCF2.,*^TKN;:J[FPS5U]%.X61RE_X7:;5Y]4T_6;O2
M;BZC6.X\E(W67;]UL.K89?[U+/X3L9/"+>&5FN$M?E_>;]TA82"3<6;N6KJJ
M*+A9',ZUX?DU34=/U&#5KBPNM/\ ,$;P1H^[>H5LAE;^[4T>CW3:7=V.H:O-
M??:4:/S#$D9C5EV_+M6N@HI7'8Y#6O!6FZYX4L_#MY-,J6BQB*X1L2(47;N_
M%<@_[U6=:T"/5A9S)=36E[92>9;7,&-R,5VMP?E*E>U=-13N*R.;T70AI5S=
MWEU?37]]=D&6XFVK\J_=4*O"J/ZU0TSPGJ6D00V=AXJO$LX79EA:W@;Y6;<5
0SMSWKLZ*+A9"T444BC__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
